PRISM BioLab a Receptor.AI oznámili spoluprácu na objavovaní nových molekúl, ktorá spája technológiu PepMetics® s umelou inteligenciou[6]. The goal of this collaboration is to design orally available small molecules by combining PepMetics® chemistry with AI-driven approaches[6]. The collaboration focuses on metabolic diseases[6]. PepMetics® technology represents a unique class of small molecules that mimic the three-dimensional structures of alpha-helices and beta-turns, structures commonly found in protein interactions[4]. The integration of AI and physics-based technologies has the potential to improve the efficiency of drug discovery and reduce the time required to develop new drugs[1]. PRISM BioLab is a Japanese biotechnology company specializing in the discovery of small molecules that inhibit interactions between proteins[4].